BD partners with Casella to pilot circularity program to assess feasibility of recycling BD syringes discarded by healthcare facilities back into manufacturing process; challenges include safe handling, treating, sterilizing of bio-hazardous materials

Sample article from our Tissue & Hygiene

February 15, 2023 (press release) –

Both companies are working to help reduce environmental impact of the BD syringe portfolio in health care facilities

By Chee Lum, vice president and general manager of Injection Systems at BD

Over the last decade, Casella and BD have partnered to recover, process and recycle waste at BD sites across the U.S., growing from 12 sites in 2013 to now more than 30 locations. This waste includes various plastics, glass and metals across many product lines that would have previously been disposed in a landfill or waste management facility.

Specific to our injection systems product lines and the sites supported by Casella, we are effectively recycling 100 percent of the non-saleable product (such as off-specification syringes and related manufacturing waste) generated from our manufacturing process. Essentially, we are landfill free! Using advanced techniques, we have increased our recycling rate of these material streams by 255 percent over the course of our partnership. For a company like BD that produces billions of syringes every year to enable various clinical applications and routine vaccinations for the flu, COVID-19 and childhood immunizations around the world, this amounts to a significant reduction in the environmental impact of our injection systems product portfolio.

As we take the next step in our sustainability efforts, we are piloting a next-generation circularity program to extend recovery efforts to BD syringes discarded by health care facilities. The pilot will assess feasibility of recycling these products back into the manufacturing process, creating additional local sourcing options and alleviating pressures on the critically challenged supply chain system.

Health care facilities are a major consumer of syringes and represent a key opportunity for reclaiming these products, which have been particularly difficult to recycle due to the various components and steps involved in the process, including safe handling of bio-hazardous material and treating and sterilizing materials before they can be re-introduced for recycling.  

“As the idea of what it means to live in a circular economy gains momentum, we are uniquely positioned to help enable more people, businesses and industries achieve their circularity goals,” said John W. Casella, chairman and CEO at Casella. “This project is an example of what can happen when we invest alongside our customers to create innovative and operationally sound solutions that advance toward a common goal.”
The team will focus on collection, treatment and scaling of solutions while also evaluating a variety of mechanical and advanced recycling capabilities for processing BD products after disposal in health care settings. Initial results are expected in the first half of 2023. 

The opportunity to drive innovation around material sustainability by building a circular value chain for managing post-consumer health care plastics furthers our commitment to addressing and managing the most relevant environmental issues facing our business and stakeholders today. We know work like this can make a lasting, positive impact, which is why we continue to challenge ourselves and our partners to find these opportunities to grow, improve and do what is right. Both BD and Casella are committed to helping build systems that enable short- and long-term value and sustainability. 

For more information about BD 2030+ environmental, social and governance goals, visit https://news.bd.com/esg. To learn more Casella, visit the company’s website at www.casella.com. 

* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order tissue & hygiene coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.